Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗
Director Gary Roubin buys 90,000 shares of unprofitable biotech stock trading well below recent highs.
Gary Roubin, a director at InspireMD, purchased a substantial stake in the company as it trades significantly below its recent highs and faces mounting losses. This is his third open-market purchase within roughly two years, continuing a pattern of accumulation at this ticker. His most recent prior buy at this company gained value in the near term but declined over a longer horizon, and the current purchase comes at even lower prices—suggesting he continues to see opportunity despite the stock's downward pressure. However, the company's financial fundamentals are deeply challenged: it is unprofitable with shrinking revenue, and the stock has fallen sharply over recent months, indicating either a turnaround bet by a director with inside knowledge or a contrarian accumulation in a struggling business. The mixed outcome from his prior purchase—gains that reversed into losses—underscores the risk profile of this trade.
Director ROUBIN GARY S buys 41,322 shares at $2.42; 3 other insiders also bought in past 14 days (cluster)
ROUBIN GARY S purchased 41,322 shares at $2.42 on 2025-07-30, raising his holdings to 608,425 shares and representing a +7.3% increase from prior holdings. This buy occurs as part of a cluster pattern, with 3 other insiders also buying within the past 14 days. At the same ticker (NSPR), his one prior buy on 2023-11-30 posted a 90d return of +9.4%. The company posted revenue of $1,529,000.00 with a net loss of $-11,166,000.00 in the latest quarter and operates unprofitably on a full-year basis, though annual revenue growth stands at +13.0%. The 30-day price action has been positive (+20.6%), though shares remain -27.3% below their 52-week high of $3.70.
